What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther
  
Rare disease studies could benefit from timeline extensions if they are struggling to recruit patients (Shutterstock)

More from Clinical Trials

More from Pathways & Standards